Skip to main content
. 2013 Jul 25;11:171. doi: 10.1186/1741-7015-11-171

Table 2.

Rate ratios for immune-mediated diseases following admission for rickets, osteomalacia or vitamin D deficiency, combined

Disease O E RR (95% CI) P-value
Addison’s disease
21
3
7.2 (4.4 to 11.0)
<0.001
Ankylosing spondylitis1
16
8.2
2.0 (1.1 to 3.2)
0.01
Asthma (aged 5 to 54)2
150
375.5
0.4 (0.3 to 0.5)
<0.001
Autoimmune hemolytic anemia
6
2.2
2.7 (1.0 to 5.9)
0.03
Chronic active hepatitis
6
1
6.2 (2.3 to 13.5)
<0.001
Celiac disease3
78
14.3
5.5 (4.3 to 6.9)
<0.001
Crohn’s disease3
47
17.9
2.6 (1.9 to 3.5)
<0.001
Diabetes mellitus (aged 0 to 29)4
7
1.8
3.9 (1.6 to 8.1)
<0.001
Hashimoto’s
6
2.8
2.1 (0.8 to 4.6)
0.11
Idiopathic thrombocyt. purpura
11
8.3
1.3 (0.7 to 2.4)
0.44
Multiple sclerosis5
15
13.1
1.1 (0.6 to 1.9)
0.7
Myxoedema
335
520.4
0.6 (0.6 to 0.7)
<0.001
Pemphigoid
13
4.9
2.7 (1.4 to 4.5)
0.001
Pernicious anemia
60
35.7
1.7 (1.3 to 2.2)
<0.001
Polymyositis
5
1
5.1 (1.6 to 11.9)
<0.001
Primary biliary cirrhosis
12
4.4
2.8 (1.4 to 4.8)
0.001
Psoriasis
29
44.2
0.7 (0.4 to 0.9)
0.03
Rheumatoid arthritis1
158
126.2
1.3 (1.1 to 1.5)
0.005
Scleroderma
6
3.4
1.8 (0.7 to 3.9)
0.25
Sjogren’s syndrome
20
9.4
2.1 (1.3 to 3.3)
0.001
Systemic lupus erythematosus
33
8.1
4.1 (2.8 to 5.8)
<0.001
Thyrotoxicosis
100
57.7
1.7 (1.4 to 2.1)
<0.001
Ulcerative colitis3 32 25.2 1.3 (0.9 to 1.8) 0.21

O Observed number of cases, E Expected number, RR Rate ratio, 95% CI 95% Confidence interval.

1Hip replacement and knee replacement were excluded from the reference cohort.

2Nasal polyp and deflected septum were excluded from the reference cohort.

3Hemorrhoids, appendectomy and cholelithiasis were excluded from the reference cohort.

4Cataracts were excluded from the reference cohort.

5Limb fractures, dislocations, superficial injury, squint and head injury were excluded from the reference cohort.

Diseases studied, but with fewer than five observed cases: dermatomyositis, Goodpasture’s syndrome, myasthenia gravis, pemphigus, polyarteritis nodosa.